Cataract Surgery Stephen G. Slade MD, FACS
13
1 Cataract Surgery Stephen G. Slade MD, FACS
description
Cataract Surgery Stephen G. Slade MD, FACS. Financial Disclosure. Alcon, AMO, B&L Consultant, Clarity, NuLens, RVO, Technolas. This presentation represents the speaker’s professional experience. US Cataract Market. 18,900,000 Global Procedures 2010 3,261,000 US Procedures - PowerPoint PPT Presentation
Transcript of Cataract Surgery Stephen G. Slade MD, FACS
1
Cataract SurgeryStephen G. Slade MD, FACS
2
Financial Disclosure
Alcon, AMO, B&L Consultant, Clarity, NuLens, RVO,
Technolas
2This presentation represents the speaker’s professional experience.
3
• 18,900,000 Global Procedures 201018,900,000 Global Procedures 2010
• 3,261,000 US Procedures3,261,000 US Procedures
• 900 million US Equipment and Packs900 million US Equipment and Packs
• 85 million US Presbyopes85 million US Presbyopes
• 72% with 0.5 D or greater Astigmatism72% with 0.5 D or greater Astigmatism
US Cataract MarketUS Cataract Market
Medicare, Marketscope
4
US Eye SurgeonsUS Eye Surgeons
Cataract Only Surgeons 4,990
Refractive Only 1,350
Cataract / Refractive Surgeons 2,260
Total 8,600
Marketscope Surveys
5
6
Is Cataract Surgery Effective Enough?Is Cataract Surgery Effective Enough?
20/40 or better
20/40 or better
20/20 or better
20/20 or better
20/40 and J3 or better
20/40 and J3 or better
20/25 and J1 or better
20/25 and J1 or better
75%75%
100%100%
85%85%
35%35%* Adapted from FDA clinical data for Crystalens and Wavelight Trials Wavelight FDA Trial, Myopia Astigmatism. Crystalens AT 45 FDA
* Adapted from FDA clinical data for Crystalens and Wavelight Trials Wavelight FDA Trial, Myopia Astigmatism. Crystalens AT 45 FDA
Only 6.4% penetration rate
Visual Outcomes less than LASIK
No safety improvement
Surgeon confidence lower
Only 6.4% penetration rate
Visual Outcomes less than LASIK
No safety improvement
Surgeon confidence lower
7
Medicare vs Private Pay
7
Source: 2007 Medicare Data
66% Medicare
22% Non Medicare
12% Medicare Managed Care
8
US Surgeries by Ownership
Physician Owned ASC 60.6%
Corporate Owned ASC 17.1%
Hospital Owned ASC 22.3%
Source MarketScope
9
Cataract Surgeons by Volume
200-59947.2%
600-119917.9% 1200-1599
2.6%
>16001.5%<100
13.3%100-19917.5%
Source MarketScope
10
What percentage of your eligible patients elected to receive premium IOLs in the past 3 months?
A. 0% to 10%B. 11% to 20%C. 21% to 30%D. Greater than 30%
Question #1
11
What premium lens is your lens of choice for your patients?
A. Crystalens 5.0B. Crystalens HDC. Crystalens AOD. Acrysof ReSTOR IOL (+3.0D)E. Tecnis MFF. AcrySof ToricG. OtherH. None, I prefer monofocal IOLs
Question #2
12
What is the most important distance to be on target for in the Premium Channel?
A. DistanceB. IntermediateC. Near
Question #3
13
If it was your own eye, which lens would you select?
A. AcrySof Toric IOLB. Tecnis Multifocal IOLC. Crystalens 5.0D. Crystalens HDE. Crystalens AOF. AcrySof ReSTOR IOL (+3.0)
Question #4
